About Asta Bio

The startup utilizes 211-Astatine, a highly effective alpha-emitting radioisotope, in conjunction with proprietary Radiobody™ targeting molecules to deliver precise radiation that disrupts DNA in tumor cells. This method effectively targets cancerous cells while preserving surrounding healthy tissue, thereby reducing side effects and improving treatment outcomes.

```xml <problem> Traditional cancer treatments often damage healthy tissues alongside cancerous cells, leading to significant side effects and reduced quality of life for patients. Effective cancer therapy requires precise targeting of tumor cells to maximize efficacy while minimizing harm to surrounding healthy tissue. </problem> <solution> This startup is developing a targeted radiotherapy approach that combines the alpha-emitting radioisotope 211-Astatine with proprietary Radiobody™ targeting molecules. This combination allows for precise delivery of radiation directly to tumor cells, disrupting their DNA and causing cell death. By selectively targeting cancer cells, this method aims to minimize damage to healthy tissues, potentially reducing side effects and improving treatment outcomes compared to traditional radiation therapies. The Radiobody™ molecules are designed to bind specifically to cancer cells, ensuring that the radiation is delivered where it is needed most. </solution> <features> - Utilizes 211-Astatine, an alpha-emitting radioisotope, for potent and localized radiation delivery. - Employs proprietary Radiobody™ targeting molecules to selectively bind to tumor cells. - Designed to disrupt DNA within cancer cells, leading to cell death. - Aims to minimize damage to surrounding healthy tissues, reducing side effects. - Multivalent single-domain antibodies enhance targeting precision. </features> <target_audience> The primary target audience includes cancer patients seeking more effective treatment options with fewer side effects, as well as oncologists and medical professionals looking for advanced radiotherapy solutions. </target_audience> ```

What does Asta Bio do?

Where is Asta Bio located?

Asta Bio is based in Boston, United States.

When was Asta Bio founded?

Asta Bio was founded in 2024.

Location

Boston, United States

Founded

2024

Employees

3 employees

Major Investors

SOSV

Looking for specific startups?

Try our free semantic startup search

Asta Bio

Score: 100/100

AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

astabiotx.com 100+

Crunchbase

Founded 2024 – Boston, United States

Funding

Major Investors

SOSV

Team (<5)

No team information available. Click "Fetch founders" to run a focused founder search.

Company Description

Problem

Traditional cancer treatments often damage healthy tissues alongside cancerous cells, leading to significant side effects and reduced quality of life for patients. Effective cancer therapy requires precise targeting of tumor cells to maximize efficacy while minimizing harm to surrounding healthy tissue.

Solution

This startup is developing a targeted radiotherapy approach that combines the alpha-emitting radioisotope 211-Astatine with proprietary Radiobody™ targeting molecules. This combination allows for precise delivery of radiation directly to tumor cells, disrupting their DNA and causing cell death. By selectively targeting cancer cells, this method aims to minimize damage to healthy tissues, potentially reducing side effects and improving treatment outcomes compared to traditional radiation therapies. The Radiobody™ molecules are designed to bind specifically to cancer cells, ensuring that the radiation is delivered where it is needed most.

Features

Utilizes 211-Astatine, an alpha-emitting radioisotope, for potent and localized radiation delivery.

Employs proprietary Radiobody™ targeting molecules to selectively bind to tumor cells.

Designed to disrupt DNA within cancer cells, leading to cell death.

Aims to minimize damage to surrounding healthy tissues, reducing side effects.

Multivalent single-domain antibodies enhance targeting precision.

Target Audience

The primary target audience includes cancer patients seeking more effective treatment options with fewer side effects, as well as oncologists and medical professionals looking for advanced radiotherapy solutions.